Author: p539124

02 April, 2020 in Allgemein

Successful follow-up financing for Pantherna Therapeutics’ development programs to fight Acute Respiratory Distress Syndrome

26 March, 2020 in Allgemein

Pantherna Therapeutics GmbH and PROVIREX Genome Editing Therapies GmbH are developing lipid-based delivery systems for mRNA-directed genome editing of lymphocytes for the treatment of HIV and other life-threatening persistent viral diseases

20 February, 2020 in Allgemein

Pantherna Therapeutics presented at the RNA Therapeutics Conference in London, UK

08 November, 2019 in Allgemein

Pantherna Therapeutics to present at BIO-Europe 2019

01 November, 2019 in Allgemein

Pantherna Therapeutics to present at mRNA Health Conference 2019

02 October, 2019 in Allgemein

Pantherna Therapeutics to present at the Creative Transformative Medicine Europe User Group Meeting

03 July, 2019 in Allgemein

“First-in-Class“ mRNA-therapeutics for vascular diseases: Pantherna Therapeutics receives 7-digit investment

17 October, 2018 in Allgemein

Pantherna Therapeutics participated as a finalist at BioRiver Boost! 2018 in Wuppertal

01 August, 2018 in Allgemein

Pantherna Therapeutics filed its first patent application “Recombinant nucleic acid construct”

23 April, 2018 in Allgemein

Pantherna Therapeutics presented at Biovaria in Munich